This, as reported by RIA Novosti, was reported in the press service of Rospotrebnadzor with reference to the response of "Vector".
“The introduction of one dose of the EpiVacCorona vaccine will not give an immune response that is optimal in strength and duration,” the center said.
Vektor said that vaccination with a single dose is possible in the case of previously ill COVID-19, while this is currently not regulated and requires additional research.
Also in "Vector" reported that the production of antibodies to coronavirus in patients with COVID-19 after vaccination may occur faster, but there is no reason to believe that there will be more antibodies.
Earlier it was reported that "Vector" is studying a sample of the coronavirus strain detected in Britain.